SCHEMBL26467455

SCHEMBL26467455

C(/C=C/c1nc2ccccc2s1)=C\c1cnccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.45
MAPT P10636 7/20 0.45
KMT2A Q03164 7/20 0.45
MEN1 O00255 5/20 0.45
TDP1 Q9NUW8 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
APP P05067 1/20 0.43
INSR P06213 1/20 0.43
NCOA1 Q15788 1/20 0.43
NPC1 O15118 7/20 0.42
HTT P42858 2/20 0.42
PKM P14618 1/20 0.42
SNCA P37840 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26467441 0.85 MAPT (0.51) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL28505896 0.85 MAPT (0.51) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL26467442 0.79 RAB9A (0.49) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL26467491 0.77 MAPT (0.54) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL710480 0.76 RAB9A (0.55) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL710481 0.76 RAB9A (0.55) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL31074949 0.76 MAPT (0.54) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL7465197 0.76 MAPT (0.54) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL7465202 0.76 MAPT (0.54) RAB9AMAPTKMT2AMEN1TDP1
SCHEMBL26467465 0.75 MAPT (0.49) RAB9AMAPTKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 MAPT, PSEN1, PSEN2 RAB9A 1002/4885MAPT 1/4885KMT2A 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.